Evidence map›Paper›PMID 33986302›Full record

ArticleScientific reports2021

Development of P301S tau seeded organotypic hippocampal slice cultures to study potential therapeutics.

James M McCarthy, Jasmeet Virdee, Jessica Brown, Daniel Ursu, Zeshan Ahmed, Annalisa Cavallini, Hugh N Nuthall

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

James M McCarthy *Neuroscience, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
Jasmeet Virdee *Neuroscience, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
Jessica BrownNeuroscience, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
Daniel UrsuNeuroscience, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
Zeshan AhmedNeuroscience, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
Annalisa CavalliniNeuroscience, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.
Hugh N NuthallNeuroscience, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK. nuthall_hugh@lilly.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracellular tau inclusions are a pathological hallmark of Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration and other sporadic neurodegenerative tauopathies. Recent in vitro and in vivo studies have shown that tau aggregates may spread to neighbouring cells and functionally connected brain regions, where they can seed further tau aggregation. This process is referred to as tau propagation. Here we describe an ex vivo system using organotypic hippocampal slice cultures (OHCs) which recapitulates aspects of this phenomenon. OHCs are explants of hippocampal tissue which may be maintained in culture for months. They maintain their synaptic connections and multicellular 3D architecture whilst also permitting direct control of the environment and direct access for various analysis types. We inoculated OHCs prepared from P301S mouse pups with brain homogenate from terminally ill P301S mice and then examined the slices for viability and the production and localization of insoluble phosphorylated tau. We show that following seeding, phosphorylated insoluble tau accumulate in a time and concentration dependent manner within OHCs. Furthermore, we show the ability of the conformation dependent anti-tau antibody, MC1, to compromise tau accrual in OHCs, thus showcasing the potential of this therapeutic approach and the utility of OHCs as an ex vivo model system for assessing such therapeutics.

Indexed as

Alzheimer DiseaseAnimalsHippocampusIn Vitro TechniquesMiceMice, TransgenicPhosphorylationTauopathies

Identifiers

PMID33986302
PMCPMC8119691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.